Helminth infections induce Th2-type biased immune responses. Although the mechanisms involved in this phenomenonare not yet clearly defined, antigen-presenting cells (APC) could play an important role in this process. Here, we have used peritoneal macrophages (F4/80؉) recruited at different times after challenge with Taenia crassiceps as APC and tested their ability to regulate Th1/Th2 differentiation. Macrophages from acute infections produced high levels of interleukin-12 (IL-12) and nitric oxide (NO), paralleled with low levels of IL-6 and prostaglandin E 2 (PGE 2 ) and with the ability to induce strong antigen-specific CD4؉ T-cell proliferation in response to nonrelated antigens. In contrast, macrophages from chronic infections produced higher levels of IL-6 and PGE 2 and had suppressed production of IL-12 and NO, associated with a poor ability to induce antigen-specific proliferation in CD4 ؉ T cells. Failure to induce proliferation was not due to a deficient expression of accessory molecules, since major histocompatibility complex class II, CD40, and B7-2 were up-regulated, together with CD23 and CCR5 as infection progressed. These macrophages from chronic infections were able to bias CD4 ؉ T cells to produce IL-4 but not gamma interferon (IFN-␥), contrary to macrophages from acute infections. Blockade of B7-2 and IL-6 and inhibition of PGE 2 failed to restore the proliferative response in CD4 ؉ T cells. Furthermore, studies using STAT6 ؊/؊ mice revealed that STAT6-mediated signaling was essential for the expansion of these alternatively activated macrophages. These data demonstrate that helminth infections can induce different macrophage populations that have Th2-biasing properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.